Answers are grounded in this paper and cite their sources.
Background To study the efficacy of mixed topical regimens with hyaluronate, trehalose, and steroidal anti-inflammatory drugs in the treatment of intense ocular surface disease (OSD) in patients under topical antiglaucoma agents. Methods: A retrospective evaluation was conducted of 7415 medical records of consecutive patients visiting a glaucoma center throughout a 2-year period. The analysis included cases with complete information for patients under preserved topical antiglaucoma treatment who were diagnosed with ocular surface disease (OSD), the severity of which was determined using the OSD Index (OSDI) score. Variables investigated were signs and symptoms related to OSD and the type and duration of topical treatment. The efficacy of two mixed-treatment regimens containing a tear substitute without preservatives and a topical steroid were compared in patients with moderate/severe OSD. Treatments differed in the administration of trehalose (T+) or not (T-). Results: Of 5158 cases under topical antiglaucoma treatment, 2634 (51.06%) showed some signs of OSD, with 725 cases showing moderate/severe OSD. Of these 725 cases, 396 and 329 cases were placed in the T + and T- groups, respectively. In the T + group, a global clinical improvement of 76.47% (299/391) was found, versus 58.38% (188/322; p = 0.024) in the T- group. The outcome variables (OSDI, TBUT, and corneal fluorescein staining) improved significantly in both groups between their initial and final visits (at least two months apart). The mean of these variables was significantly better in the T + group during the final visit (p ≤ 0.01). Conclusion: An improvement in OSD variables associated with antiglaucoma drugs was observed, particularly in the group that used trehalose. Therefore, this agent should be considered for routine use in patients with OSD, especially for cases of moderate to severe intensity; it is most useful when associated with non-preserved artificial tears and topical steroids.
No takes yet. Share an insight, caveat, or question.
Giorgi-Sandoval et al. (2022) studied this question.